Literature DB >> 31436550

Management of Five Hundred Patients With Gut Failure at a Single Center: Surgical Innovation Versus Transplantation With a Novel Predictive Model.

Kareem M Abu-Elmagd1, Sherif R Armanyous1, Masato Fujiki1, Neha R Parekh1, Mohammed Osman1, Marissa Scalish1, Elizabeth Newhouse1, Yasser Fouda1, Elizabeth Lennon1, Abdullah Shatnawei1, Donald Kirby1, Ezra Steiger1, Ajai Khanna2, Kadakkal Radhakrishnan1, Cristiano Quintini1, Koji Hashimoto1, Julie Barnes1, Guilherme Costa1.   

Abstract

OBJECTIVE(S): To define the evolving role of integrative surgical management including transplantation for patients gut failure (GF).
METHODS: A total of 500 patients with total parenteral nutrition-dependent catastrophic and chronic GF were referred for surgical intervention particularly transplantation and comprised the study population. With a mean age of 45 ± 17 years, 477 (95%) were adults and 23 (5%) were children. Management strategy was guided by clinical status, splanchnic organ functions, anatomy of residual gut, and cause of GF. Surgery was performed in 462 (92%) patients and 38 (8%) continued medical treatment. Definitive autologous gut reconstruction (AGR) was achievable in 378 (82%), primary transplant in 42 (9%), and AGR followed by transplant in 42 (9%). The 84 transplant recipients received 94 allografts; 67 (71%) liver-free and 27 (29%) liver-contained. The 420 AGR patients received a total of 790 reconstructive and remodeling procedures including primary reconstruction, interposition alimentary-conduits, intestinal/colonic lengthening, and reductive/decompressive surgery. Glucagon-like peptide-2 was used in 17 patients.
RESULTS: Overall patient survival was 86% at 1-year and 68% at 5-years with restored nutritional autonomy (RNA) in 63% and 78%, respectively. Surgery achieved a 5-year survival of 70% with 82% RNA. AGR achieved better long-term survival and transplantation better (P = 0.03) re-established nutritional autonomy. Both AGR and transplant were cost effective and quality of life better improved after AGR. A model to predict RNA after AGR was developed computing anatomy of reconstructed gut, total parenteral nutrition requirements, cause of GF, and serum bilirubin.
CONCLUSIONS: Surgical integration is an effective management strategy for GF. Further progress is foreseen with the herein-described novel techniques and established RNA predictive model.

Entities:  

Mesh:

Year:  2019        PMID: 31436550     DOI: 10.1097/SLA.0000000000003523

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  5 in total

1.  Intellectual property and data ownership in the age of video recording in the operating room.

Authors:  Filippo Filicori; Poppy Addison
Journal:  Surg Endosc       Date:  2021-09-01       Impact factor: 3.453

2.  Short-Bowel Syndrome: Epidemiology, Hospitalization Trends, In-Hospital Mortality, and Healthcare Utilization.

Authors:  Mohamed Tausif Siddiqui; Wael Al-Yaman; Amandeep Singh; Donald F Kirby
Journal:  JPEN J Parenter Enteral Nutr       Date:  2020-12-17       Impact factor: 3.896

Review 3.  Comparing bowel lengthening procedures: which, when, and why?

Authors:  Jasper B van Praagh; H Sijbrand Hofker; Jan-Willem Haveman
Journal:  Curr Opin Organ Transplant       Date:  2022-04-01       Impact factor: 2.640

Review 4.  State-of-the-art colorectal disease: conservative surgical management of intestinal failure in adults.

Authors:  Mathilde Aubert; Diane Mege; Lore Billiauws; Francisca Joly; Yves Panis
Journal:  Int J Colorectal Dis       Date:  2021-02-24       Impact factor: 2.571

5.  Five Hundred Patients With Gut Malrotation: Thirty Years of Experience With the Introduction of a New Surgical Procedure.

Authors:  Kareem Abu-Elmagd; George Mazariegos; Sherif Armanyous; Neha Parekh; Ayat ElSherif; Ajai Khanna; Beverly Kosmach-Park; Giuseppe D'Amico; Masato Fujiki; Mohammed Osman; Marissa Scalish; Amanda Pruchnicki; Elizabeth Newhouse; Ahmed A Abdelshafy; Erick Remer; Guilherme Costa; R Matthew Walsh
Journal:  Ann Surg       Date:  2021-10-01       Impact factor: 12.969

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.